Discover how allocation impacts long-term outcomes for the transplant recipient and liver graft at this session. Speakers will address ways to improve the ability to interpret and identify the significance of long-term, post-transplant liver biopsy findings and offer tools to expand one’s perspective on individualizing immunosuppression to optimize long-term outcomes for the allograft and recipient.

AASLD Guideline/Guidance Statements on treating hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and alcohol-related liver disease (ALD) are now updated to reflect data published since 2010, when the previous versions were released. At this session, the guidelines’ authors will highlight important changes hepatologists should know and discuss controversial or challenging issues in treating patients with these chronic liver diseases.

AASLD members at all career stages are increasingly involved in social media like Twitter. This timely, lively discussion will explore the risks and benefits of tweeting from the perspectives of trainees, researchers, division leaders and journal editors.

Anoop N. Koshy, Omar Farouque, Paul Calafiore, Paul J. Gow – 11 November 2019

Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly Watt, Samuel S. Lee, the Cirrhotic Cardiomyopathy Consortium: The Cirrhotic Cardiomyopathy Consortium is a multidisciplinary international group whose focus is to improve the understanding of cirrhotic cardiomyopathy, its management and outcomes – 11 November 2019

In the world's poorest nations, the appalling loss of life from easily treated or preventable illnesses represents a moral tragedy. This year's President's Choice Lecture explores potential strategies to correct this inequity, including collaborative partnerships among medical professionals, ways to accurately measure the impact of global disease management efforts and the innovative solutions necessary to accomplish this great task.

Patient and caregiver education, and transition to care are important aspects for hospital discharge. At this informative program, experts will review multidisciplinary strategies to optimize discharge planning and share innovative models of outpatient care in liver disease, including empowering patients and caregivers, decreasing risk factors and the incidence of hospital readmissions, and reducing costs.

Several NIH institutes showcase programs, innovations and opportunities to the AASLD membership at this informative event. Representatives of the NCI, NIDDK, NIAID and NIAAA will present areas of mutual interest to the institute and AASLD membership, including liver cancer, NASH, viral hepatitis and alcohol use disorder. This is a unique opportunity to learn more about interagency collaboration and funding opportunities.

If you are a general practitioner caring for patients with a variety of liver diseases, this hepatology update is designed for your needs. Review significant new findings in hepatology and how they may affect current clinical practice, ask questions and discuss challenges faced in daily clinical settings.

Experts share new research in molecular hepatocarcinogenesis in the setting of NASH at this program, including global obesity trends, the association of metabolic syndrome and HCC, and HCC surveillance in patients with NASH/metabolic syndrome. They will present and compare evidence on HCC diagnosis and management specific to patients with obesity that may be applied to clinical practice.